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Abstract: Thiosemicarbazones continue to attract the interest of researchers as potential anticancer
drugs. For example, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, or triapine, is the most
well-known representative of this class of compounds that has entered multiple phase I and II clinical
trials. Two new triapine derivatives HL1 and HL2 were prepared by condensation reactions of
2-pyridinamidrazone and S-methylisothiosemicarbazidium chloride with 3-N-(tert-butyloxycarbonyl)
amino-pyridine-2-carboxaldehyde, followed by a Boc-deprotection procedure. Subsequent reaction
of HL1 and HL2 with CuCl2·2H2O in 1:1 molar ratio in methanol produced the complexes
[CuII(HL1)Cl2]·H2O (1·H2O) and [CuII(HL2)Cl2] (2). The reaction of HL2 with Fe(NO3)3·9H2O
in 2:1 molar ratio in the presence of triethylamine afforded the complex [FeIII(L2)2]NO3·0.75H2O
(3·0.75H2O), in which the isothiosemicarbazone acts as a tridentate monoanionic ligand. The crystal
structures of HL1, HL2 and metal complexes 1 and 2 were determined by single crystal X-ray
diffraction. The UV-Vis and EPR spectroelectrochemical measurements revealed that complexes 1
and 2 underwent irreversible reduction of Cu(II) with subsequent ligand release, while 3 showed
an almost reversible electrochemical reduction in dimethyl sulfoxide (DMSO). Aqueous solution
behaviour of HL1 and 1, as well as of HL2 and its complex 2, was monitored as well. Complexes
1−3 were tested against ovarian carcinoma cells, as well as noncancerous embryonic kidney cells,
in comparison to respective free ligands, triapine and cisplatin. While the free ligands HL1 and
HL2 were devoid of antiproliferative activity, their respective metal complexes showed remarkable
antiproliferative activity in a micromolar concentration range. The activity was not related to
the inhibition of ribonucleotide reductase (RNR) R2 protein, but rather to cancer cell homeostasis
disturbance—leading to the disruption of cancer cell signalling.
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1. Introduction
α-N-Heterocyclic thiosemicarbazones (TSCs) attract considerable attention since their remarkable
antiproliferative properties have been discovered [1]. The most promising representative of this group
of compounds is 3-aminopyridine-2-carboxaldehyde thiosemicarbazone or triapine (3-AP), which has
already entered more than 30 phase I and II clinical trials [2–4]. 3-AP was also tested in various
combination regimens and was shown to enhance the activity of other anticancer drugs, such as
cisplatin [2,5], gemcitabine [6], doxorubicin [7], irinotecan [4]. It is believed that the mode of action
of 3-AP is based on the effective inhibition of RNR [8–10] as a result of Fe(II) chelation from the
diferric-tyrosyl cofactor, followed by the generation of reactive oxygen species (ROS) [11]. However,
despite the promising anticancer effects in vitro and in vivo, the use of 3-AP in patients is associated
with side-effects, i.e., neutropenia [12], methemoglobinemia [13], nausea, vomiting etc. Additionally,
several types of solid tumours demonstrated resistance to 3-AP treatment [12,14–16]. TSCs are known to
efficiently chelate first-row transition metals, 3-AP, and its analogues were coordinated to endogenous
metals, such as Cu and Fe [17–20]. TSC coordination to essential metals often decreases overall toxicity
of the drug molecules [21] and increases their anticancer activity, due to the synergistic action of
TSCs and the metal centre [19–21]. In general, numerous Cu(II) complexes of thiosemicarbazones
were characterised by superior anticancer activity when compared to that of the free ligands [22–26].
In contrast, coordination to Fe(III) prior to the administration of the compound did not always result
in the improvement of cytotoxicity [17,27]. Interestingly, both Cu(II) and Fe(III) complexes of 3-AP
were less active than 3-AP itself [10,17], possibly due to their high thermodynamic stability and lower
cell uptake kinetics [28].
Carboxamidrazones structurally resemble thiosemicarbazones, but, surprisingly, their anticancer
effects were not extensively studied. These compounds demonstrated antiproliferative activity in the
micromolar range and good selectivity to cancer cells over healthy cells [29,30]. Similarly to Cu(II)-TSC
complexes, coordination of carboxamidrazones to Cu(II) improved the cytotoxicity. However, there are
only several examples of reported Cu(II)-carboxamidrazone complexes [31–33]. Therefore, we have
prepared novel pyridinamidrazone and S-methylisothiosemicarbazone, structurally related to 3-AP,
as well as Cu(II) and Fe(III) complexes thereof (Scheme 1) and investigated their potential as anticancer
drugs. It should be noted that thiomethylation is known to affect the coordination behaviour of
isothiosemicarbazones toward first-row transition metals when compared to thiosemicarbazones,
so that sulfur atom is not involved in binding to the metal [34]. It might also have an effect not only on
the antiproliferative activity, but also on the underlying mechanism of action; therefore, one of the
main aims was to address this issue in the present study. All compounds were fully characterised
by analytical and spectroscopic methods. The electrochemical properties were studied by cyclic
voltammetry and UV–Vis–NIR spectroelectrochemistry. Solution stabilities of HL1 and 1, as well as of
HL2 and 2 were monitored by UV–Vis spectroscopy. The anticancer activity of novel compounds was
tested in two ovarian cancer cell lines (A2780 and A2780cis), as well as in noncancerous embryonic
kidney cell line (HEK293) and their intracellular dose-dependent accumulation investigated. The ability
of HL2 to quench the tyrosyl radical in hR2 RNR protein and of its Fe(II) complex to generate ROS
in aqueous solution, was studied as well and compared with that of 3-AP and its Fe(II) complex.
In addition, the effects of the most cytotoxic complex 2 on the key cancer cell signalling pathways
were described.
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Scheme 1. Line drawings of 3-AP (triapine), carboxamidrazone HL1 and isothiosemicarbazone HL2 
free ligands and complexes 1−3 reported in this work. Underlined labels/numbers indicate 
compounds studied by X-ray crystallography. 
2. Materials and Methods 
2.1. Chemicals 
All reagents used were received from commercial sources. 2-Cyanopyridine, CuCl2·2H2O and 
Fe(NO3)3·9H2O were purchased from Sigma-Aldrich. 2-Pyridinamidrazone was prepared as a white 
solid by the reaction of 2-cyanopyridine with excess hydrazine monohydrate as reported previously 
[35]. 3-N-(tert-Butyloxycarbonyl)amino-2-pyridinecarboxaldehyde [36] and S-
methylisothiosemicarbazidium iodide [37] were obtained, as described in the literature. The S-
methylisothiosemicarbazidium chloride was obtained from the corresponding iodide by using anion-
exchange resin. 
2.1.1. 3-Amino-2-Pyridinecarboxaldehyde 2-Pyridinamidrazone (HL1) 
To a solution of 3-N-(tert-butyloxycarbonyl)amino-2-pyridinecarboxaldehyde (0.21 g, 0.945 
mmol) and 2-pyridinamidrazone (0.13 g, 0.945 mmol) in ethanol (8 mL) 12 M HCl (0.079 mL, 0.948 
mmol) was added dropwise. The resulting solution was stirred at room temperature for 2 h, and then 
evaporated under reduced pressure to produce an orange oil. This was crystallised in vacuo to give 
Boc-HL1·HCl (C17H20N6O2·HCl, positive ion ESI-MS (MeCN/MeOH+1% H2O): m/z 341.16 [Boc-
HL1+H]+). A part of the raw product (0.25 mg, 0.66 mmol) was suspended in ethyl acetate (3 mL) and 
a solution of 4 M HCl/EtOAc (1 mL, 4 mmol) was added. The resulting yellow suspension was stirred 
at room temperature for 1 h and then at 45 °C for 2 h. The Boc-deprotection was monitored by ESI-
MS (positive ion ESI-MS (MeCN/MeOH+1% H2O): m/z 241.23 [HL1+H]+). The suspension was 
neutralised with saturated NaHCO3 (pH 7–8), then the product was extracted with ethyl acetate, 
washed with brine, dried over Na2SO4 and evaporated in vacuo to produce a yellow powder of HL1 
(C12H12N6, yield 0.12 g, 0.49 mmol, 74%). Crystals suitable for X-ray diffraction study were obtained 
in ethyl acetate/hexane mixture (1/1 v/v). Anal. Calcd for C12H12N6 (Mr = 240.26), %: C, 59.98; H, 5.03; 
N, 34.98. Found, %: C, 59.78; H, 5.15; N, 34.65. Positive ion ESI-MS for C12H12N6 (MeCN/MeOH+1% 
H2O): m/z 241.23 [HL1+H]+, 263.22 [HL1+Na]+, negative ion ESI-MS: m/z 239.09 [HL1–H]–. 1H NMR (600 
MHz, DMSO-d6) δ, ppm: 8.66 (d, J = 4.7 Hz, 1H, H6), 8.63 (s, 1H, H10), 8.28 (d, J = 7.9 Hz, 1H, H3), 7.92 
(td, J = 7.8, 1.7 Hz, 1H, H4), 7.88 (dd, J = 4.2, 1.3 Hz, 1H, H13), 7.54 (ddd, J = 7.4, 4.8, 1.0 Hz, 1H, H5), 
7.20 (dd, J = 8.3, 1.0 Hz, 1H, H15), 7.10 (brs, 2H, H7’), 7.09 (dd, J = 8.3, 4.3 Hz, 1H, H14), 6.85 (s, 2H, H16’). 
13C NMR (151 MHz, DMSO-d6) δ, ppm: 160.17 (C10), 155.03 (C7), 150.42 (C2), 148.42 (C6), 144.93 (C16), 
137.09 (C4 or C13), 137.01 (C4 or C13), 133.90 (C11), 125.36 (C5), 124.31 (C14), 121.94 (C15), 121.28 (C3). 15N 
NMR (61 MHz, DMSO-d6) δ, ppm: 349.66 (N8), 321.97 (N12), 304.04 (N1), 275.94 (N9), 76.02 (N7′), 71.27 
Sche e 1. Line drawings of 3-AP (triapine), carboxa idrazone HL1 and isothiose icarbazone HL2
free ligands and complexes 1−3 reported in this work. Underlined labels/numbers indicate compounds
studied by X-ray crystallography.
2. aterials a et o s
2.1. Chemicals
All reagents used were received from commercial sources. 2-Cyanopyridine, CuCl2·2H2O
and Fe(NO3)3·9H2O were purchased from Sigma-Aldrich. 2-Pyridinamidrazone was prepared
as a white solid by the reaction of 2-cyanopyridine with excess hydrazine monohydrate
as reported previously [35]. 3-N-(tert-Butyloxycarbonyl)amino-2-pyridinecarboxaldehyde [36]
and S-methylisothiosemicarbazidium iodide [37] were obtained, as described in the literature.
The S-methylisothiosemicarbazidium chloride was obtained from the corresponding iodide by using
anion-exchange resin.
2.1.1. 3-Amino-2-Pyridinecarboxaldehyde 2-Pyridinamidrazone (HL1)
To a solution of 3-N-(tert-butyloxycarbonyl)amino-2-pyridinecarboxaldehyde (0.21 g, 0.945 mmol)
and 2-pyridinamidrazone (0.13 g, 0.945 mmol) in ethanol (8 mL) 12 M HCl (0.079 mL, 0.948 mmol) was
added dropwise. The resulting solution was stirred at room temperature for 2 h, and then evaporated
under reduced pressure to produce an orange oil. This was crystallised in vacuo to give Boc-HL1·HCl
(C17H20N6O2·HCl, positive ion ESI-MS (MeCN/MeOH+1% H2O): m/z 341.16 [Boc-HL1+H]+). A part
of the raw product (0.25 mg, 0.66 mmol) was suspended in ethyl acetate (3 mL) and a solution of
4 M HCl/EtOAc (1 mL, 4 mmol) was added. The resulting yellow suspension was stirred at room
temperature for 1 h and then at 45 ◦C for 2 h. The Boc-deprotection was monitored by ESI-MS
(positive ion ESI-MS (MeCN/MeOH+1% H2O): m/z 241.23 [HL1+H]+). The suspension was neutralised
with saturated NaHCO3 (pH 7–8), then the product was extracted with ethyl acetate, washed with
brine, dried over Na2SO4 and evaporated in vacuo to produce a yellow powder of HL1 (C12H12N6,
yield 0.12 g, 0.49 mmol, 74%). Crystals suitable for X-ray diffraction study were obtained in ethyl
acetate/hexane mixture (1/1 v/v). Anal. Calcd for C12H12N6 (Mr = 240.26), %: C, 59.98; H, 5.03; N, 34.98.
Found, %: C, 59.78; H, 5.15; N, 34.65. Positive ion ESI-MS for C12H12N6 (MeCN/MeOH+1% H2O): m/z
241.23 [HL1+H]+, 263.22 [HL1+Na]+, negative ion ESI-MS: m/z 239.09 [HL1–H]–. 1H NMR (600 MHz,
DMSO-d6) δ, ppm: 8.66 (d, J = 4.7 Hz, 1H, H6), 8.63 (s, 1H, H10), 8.28 (d, J = 7.9 Hz, 1H, H3), 7.92
(td, J = 7.8, 1.7 Hz, 1H, H4), 7.88 (dd, J = 4.2, 1.3 Hz, 1H, H13), 7.54 (ddd, J = 7.4, 4.8, 1.0 Hz, 1H,
H5), 7.20 (dd, J = 8.3, 1.0 Hz, 1H, H15), 7.10 (brs, 2H, H7’), 7.09 (dd, J = 8.3, 4.3 Hz, 1H, H14), 6.85
(s, 2H, H16’). 13C NMR (151 MHz, DMSO-d6) δ, ppm: 160.17 (C10), 155.03 (C7), 150.42 (C2), 148.42 (C6),
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144.93 (C16), 137.09 (C4 or C13), 137.01 (C4 or C13), 133.90 (C11), 125.36 (C5), 124.31 (C14), 121.94 (C15),
121.28 (C3). 15N NMR (61 MHz, DMSO-d6) δ, ppm: 349.66 (N8), 321.97 (N12), 304.04 (N1), 275.94 (N9),
76.02 (N7′), 71.27 (N16′). The atom numbering for the assignment of resonances see in Scheme S3 in
Supporting Information.
2.1.2. [Cu(HL1)Cl2]·H2O·(1·H2O)
To a solution of HL1 (0.100 g, 0.42 mmol) in methanol (10 mL) was added a solution of copper(II)
chloride dihydrate (0.062 g, 0.36 mmol) in methanol (10 mL). The mixture was heated to 65 ◦C and
left under stirring and reflux overnight. Next day the brown precipitate was filtered off and purified
on preparative HPLC by using water/methanol as eluent (Figure S1). The final product was obtained
as brown powder after drying in vacuo. Yield: 0.031 g, 22%. Anal. Calcd for C12H12Cl2CuN6·H2O
(Mr = 392.73), %: C, 36.69; H, 3.59; N, 21.39. Found, %: C, 37.00; H, 3.32; N, 21.13. Positive ion ESI-MS
for C12H12Cl2CuN6 (MeCN/MeOH+1% H2O): m/z 338.14 [Cu(HL1)Cl]+, 303.17 [CuI(HL1)]+ (Figure S2),
negative ion ESI-MS: m/z 336.02 {[Cu(HL1)Cl]+–2H+}–, 373.98 [Cu(HL1)Cl2–H+]–. UV-Vis (DMSO),
λmax, nm (ε, M−1cm−1): 714 (139), 437 (10,326). IR (ATR, selected bands,
1 
 
ῦ max): 3209, 3114, 1636, 1578,
1538, 1235, 1151, 1052, 853, 801, 683, 660 cm−1.
2.1.3. 3-Amino-2-pyridinecarboxaldehyde S-methylisothiosemicarbazone (HL2)
3-N-(tert-Butyloxycarbonyl)amino-2-pyridinecarboxaldehyde (0.31 g, 1.4 mmol) in ethanol (6 mL)
and S-methylisothiosemicarbazidium chloride (0.20 g, 1.4 mmol) in water (2 mL) were mixed together
and 12 M HCl (0.597 mL) was added. The mixture was stirred at 70 ◦C for 3 h. After cooling to the
room temperature the solvent was removed under reduced pressure, the residue dissolved in water
and neutralised with NaHCO3. Fine yellow precipitate was filtered off, washed with ethanol, diethyl
ether and dried in vacuo. Yield: 0.19 g, 67%. Anal. Calcd for C8H11N5S (Mr = 209.27): C, 45.91; H, 5.30;
N, 33.47; S, 15.32%. Found, %: C, 46.07; H, 5.28; N, 33.29; S, 15.46. Positive ion ESI-MS for C8H11N5S
(MeCN/MeOH+1% H2O): m/z 210.06 [HL2+H]+. 1H NMR (600 MHz, DMSO-d6, Z-isomer) δ, ppm:
8.39 (s, 1H, H8), 7.83 (dd, J = 4.3, 1.5 Hz, 1H, H6), 7.13 (dd, J = 8.3, 1.1 Hz, 1H, H4), 7.04–7.01 (m, 2H,
H5 (Z-)+H5 (E-)), 6.90 (s, 2H, H13), 6.67 (s, 2H, H7), 2.39 (s, 3H, H12). 1H NMR (600 MHz, DMSO-d6,
E-isomer) δ 8.30 (s, 1H, H8), 7.82 (dd, J = 4.3, 1.5 Hz, 1H, H6), 7.08 (dd, J = 8.3, 1.1 Hz, 1H, H4), 7.04–7.01
(m, 2H, H5 (Z-)+H5 (E-)), 6.87 (s, 2H, H7), 6.82 (s, 2H, H13), 2.40 (s, 3H, H12). 13C NMR (151 MHz,
DMSO-d6, Z-isomer) δ 160.43 (C11), 157.86 (C8), 144.45 (C3), 136.88 (C6), 134.19 (C2), 123.85 (C5), 121.65
(C4), 12.30 (C12). 13C NMR (151 MHz, DMSO-d6, E-isomer) δ, ppm: 165.50 (C11), 153.74 (C8), 144.00
(C3), 136.82 (C6), 134.70 (C2), 123.41 (C5), 121.52 (C4), 12.50 (C12). 15N NMR (61 MHz, DMSO-d6,
Z-isomer) δ 70.93 (N7), 83.70 (N13), 267.43 (N10), 321.37 (N1), 348.34 (N9). 15N NMR (61 MHz, DMSO-d6,
E-isomer) δ, ppm: 66.65 (N7), 80.46 (N13), 280.47 (N10), 319.87 (N1), 357.71 (N9).
2.1.4. [Cu(HL2)Cl2] (2)
To a solution of HL2 (0.050 g, 0.24 mmol) in methanol (5 mL) was added a solution of copper(II)
chloride dihydrate (0.041 g, 0.24 mmol) in methanol (5 mL). The mixture was heated to 50 ◦C, stirred
for 10 min, and allowed to cool down to room temperature. Dark-green crystals were filtered off
next day, washed with small portions of cold methanol and dried in air. Yield: 0.034 g, 41%. Anal.
Calcd for C8H11Cl2CuN5S (Mr = 343.72), %: C, 27.95; H, 3.23; N, 20.37; S, 9.33. Found, %: C, 28.13; H,
3.30; N, 19.89; S, 8.92. Positive ion ESI-MS for C8H11Cl2CuN5S (MeCN/MeOH+1% H2O): m/z 271.15
[CuII(L2)]+; 307.13 [Cu(HL2)Cl]+; negative: m/z 304.95 [Cu(L2)Cl–H+]–. UV-Vis (MeOH), λmax, nm
(ε, M−1cm−1): 696 (122), 441 (11643), 282 (12217). IR (ATR, selected bands,
1 
 
ῦ max): 3250, 1642, 1583,
1525, 1502, 1274, 1217, 913, 877, 794, 643 cm−1.
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2.1.5. [Fe(L2)2NO3]·0.75H2O (3·0.75H2O)
To a solution of HL2 (0.059 g, 0.28 mmol) in methanol (5 mL) was added a solution of Fe(NO3)3·9H2O
(0.057 g, 0.14 mmol) in methanol (5 mL) and triethylamine (39 µL, 0.28 mmol). The mixture was heated
to 60 ◦C and stirred for 20 min. After the removal of methanol under reduced pressure, the residue
was recrystallised from ethanol to give fine black microcrystals. These were filtered off, washed with
ethanol, diethyl ether and dried in air. Yield: 0.033 g, 43%. Anal. Calcd for C16H20FeN11O3S2·0.75H2O
(Mr = 547.9), %: C, 35.07; H, 3.96; N, 28.12; S, 11.71. Found, %: C, 35.36; H, 3.73; N, 27.90; S, 11.64.
Positive ion ESI-MS for C16H20FeN11O3S2 (MeCN/MeOH+1% H2O): m/z 472.20 [Fe(L2)2]+ (Figure S3);
negative ion: m/z 470.03 [Fe(L2)2–2H+]–. UV–Vis (MeOH), λmax, nm (ε, M−1cm−1): 932 (891), 694 (590),
488 (12551), 428 (13956), 401sh, 301(15888), 266 (14206). IR (ATR, selected bands,
1 
 
ῦ max): 3214, 1646,
1579, 1528, 1466, 1319, 1268, 1142, 1057, 970, 849, 736 cm−1.
2.2. Physical Measurements
Elemental analyses were carried out in a Carlo-Erba microanalyser at the Microanalytical
Laboratory of the University of Vienna. Electrospray ionisation mass spectrometry (ESI MS) was
carried out with amazon speed ETD Bruker instrument (Bremen, Germany, m/z range 0–900,
ion positive/negative mode, 180 ◦C, heating gas N2 (5 L/min), Capillary 4500 V, End Plate Offset 500 V).
UV–Vis spectra were measured on Perkin Elmer UV/Vis spectrophotometer Lambda 35. IR spectra
were reported on a Bucker Vertex 70 Fourier transform IR spectrometer (4000–400 cm−1) using the ATR
technique. 1D (1H, 13C) and 2D (1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC, 1H-13C
HMBC, 1H-15N HSQC, 1H-15N HMBC) NMR spectra were measured on a Bruker AV NEO 500 or AV
III 600 spectrometers (Karlsruhe, Germany) in DMSO-d6 at 25 ◦C at NMR spectroscopy Centre of the
Faculty of Chemistry of the University of Vienna.
2.3. Crystallographic Structure Determination
X-ray diffraction measurements were performed on a Bruker X8 APEXII CCD (Karlsruhe,
Germany), Bruker D8 Venture (Karlsruhe, Germany) and STOE (Darmstadt, Germany) diffractometers.
Single crystals were positioned at 30, 30, 35, 40 and 40 mm from the detector, and 987, 360, 3319,
5298 and 527 frames were measured, each for 20, 3, 10, 30 and 50 s over 0.5, 0.5, 0.5, 1 and 2◦ scan
width for HL1, [H3L1a]Cl2·2H2O, HL2, 1, and 2, respectively. The data were processed using SAINT
software [38]. Crystal data, data collection parameters, and structure refinement details are given
in Table 1. The structures were solved by direct methods and refined by full-matrix least-squares
techniques. Non-H atoms were refined with anisotropic displacement parameters. H atoms were
inserted in calculated positions and refined with a riding model. The following computer programs and
hardware were used: structure solution, SHELXS-2014 and refinement, SHELXL-2014 [39]; molecular
diagrams, ORTEP [40]; computer, Intel CoreDuo. CCDC 1958520, 1958521, 1958523–1958525.
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Table 1. Crystal data and details of data collection for HL1, [H3L1a]Cl2·2H2O, HL2, [Cu(HL1)Cl2] (1)
and [Cu(HL2)Cl2] (2).
Compound HL1 [H3L1a]Cl2·2H2O HL2 1 2
empirical formula C12H12N6 C12H18Cl2N6O2 C8H11N5S C12H12Cl2CuN6 C8H11Cl2CuN5S
fw 240.28 349.22 209.28 374.72 343.72
space group Pna21 P21/c P21/c P21/c P1
a, [Å] 16.9760 (18) 8.8057 (3) 10.9320 (4) 8.3933 (3) 8.0926 (13)
b, [Å] 6.1689 (7) 28.3257 (9) 7.0723 (3) 11.5392 (2) 8.9713 (15)
c, [Å] 10.9516 (12) 6.8074 (3) 12.6838 (5) 15.1025 (5) 9.1504 (15)
α, [◦] 78.368 (7)
β, [◦] 109.7135 (14) 93.627 (2) 104.188 (2) 78.276 (6)
γ, [◦] 74.508 (6)
V [Å3] 1146.9(2) 1598.4 (1) 978.29 (7) 1418.09 (7) 619.15 (18)
Z 4 4 4 4 2
λ, [Å] 0.71073 0.71073 0.71073 1.54186 0.71073
ρcalcd, [g cm−3] 1.392 1.451 1.421 1.755 1.844
cryst size, [mm3] 0.12 × 0.10 × 0.06 0.35 × 0.10 × 0.10 0.20 × 0.18 × 0.12 0.22 × 0.04 × 0.04 0.20 × 0.18 × 0.07
T [K] 120 (2) 120(2) 130 (2) 100 (2) 200 (2)
µ, [mm−1] 0.092 0.422 0.298 5.662 2.347
R1 a 0.0329 0.0607 0.0309 0.0358 0.0555
wR2 b 0.0807 0.2349 0.0873 0.0950 0.2121
GOF c 1.099 1.180 1.048 0.958 1.071
a R1 = Σ||Fo| − |Fc||/Σ|Fo|. b wR2 = {Σ[w(Fo2 − Fc2)2]/Σ[w(Fo2)2]}1/2. c GOF = {Σ[w(Fo2 − Fc2)2]/(n − p)}1/2, where n is
the number of reflections, and p is the total number of parameters refined.
2.4. Electrochemistry and Spectroelectrochemistry
Cyclic voltammetric experiments with 0.5 mM solutions of 1–3 in 0.1 M n-Bu4NPF6 (puriss
quality from Fluka (Schwerte, Germany); dried under reduced pressure at 70 ◦C for 24 h before
use) supporting electrolyte in DMSO (SeccoSolv max. 0.025% H2O, Merck) were performed under
argon atmosphere using a three-electrode arrangement with a platinum disk or a glassy carbon
disk working electrode (from Ionode, Australia), platinum wire as a counter electrode, and silver
wire as a pseudo reference electrode. All potentials in voltammetric studies were quoted vs
ferricenium/ferrocene (Fc+/Fc) redox couple. A Heka PG310USB (Lambrecht, Germany) potentiostat
with a PotMaster 2.73 software package served for the potential control in voltammetric studies.
In situ ultraviolet-visible-near-infrared (UV–Vis–NIR) spectroscopic and spectroelectrochemical
measurements were performed on a spectrometer Avantes (Model AvaSpec-2048 × 14-USB2) in
1 cm quartz cuvette or the spectroelectrochemical cell kit (AKSTCKIT3) with the Pt-microstructured
honeycomb working electrode, purchased from Pine Research Instrumentation (Lyon, France). The cell
was positioned in the CUV-UV Cuvette Holder (Ocean Optics, Ostfildern, Germany) connected to the
diode-array UV–Vis–NIR spectrometer by optical fibres. UV–Vis–NIR spectra were processed using
the AvaSoft 7.7 software package. Halogen and deuterium lamps were used as light sources (Avantes,
Model AvaLight-DH-S-BAL, Apeldoorn, The Netherlands).
2.5. Cell Lines and Culture Conditions
Human ovarian carcinoma cells A2780 and A2780cis, and human embryonic kidney cells HEK293
were obtained from ATCC. A2780 and A2780cis cells were cultured in RPMI 1640 medium containing
10% fetal bovine serum (FBS). HEK293 cells were cultured in DMEM medium containing 10% FBS.
All cells were grown in tissue culture 25 cm2 flasks (BD Biosciences, Singapore) at 37 ◦C in a humidified
atmosphere of 95% air and 5% CO2. All drug stock solutions were prepared in DMSO, and the final
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concentration of DMSO in the medium did not exceed 1% (v/v) at which cell viability was not inhibited.
The amount of actual Cu concentration in the stock solutions was determined by ICP-OES.
2.6. Inhibition of Cell Viability Assay
The cytotoxicity of the compounds was determined by colourimetric microculture assay
(MTT assay). The cells were harvested from culture flasks by trypsinisation and seeded into Cellstar
96-well microculture plates (Greiner Bio-One, Practical Mediscience Pte Ltd, Singapore, Singapore)
at the seeding density of 6 × 104 cells per mL. After the cells were allowed to resume exponential
growth for 24 h, they were exposed to drugs at different concentrations in media for 72 h. The drugs
were diluted in complete medium at the desired concentration, and 100 µL of the drug solution
was added to each well and serially diluted to other wells. After exposure for 72 h, drug solutions
were replaced with 100 µL of MTT in media (5 mg mL−1) and incubated for an additional 45 min.
Subsequently, the medium was aspirated, and the purple formazan crystals formed in viable cells
were dissolved in 100 µL of DMSO per well. Optical densities were measured at 570 nm with a
microplate reader. The number of viable cells was expressed in terms of treated/control (T/C) values by
comparison to untreated control cells, and 50% inhibitory concentrations (IC50) were calculated from
concentration-effect curves by interpolation. The evaluation was based on means from at least three
independent experiments, each comprising six replicates per concentration level.
2.7. Intracellular Accumulation
Intracellular accumulation of 1 and 2 was determined in A2780 cells. Cells were seeded into
Cellstar 6-well plates (Greiner Bio-one) at a density of 6 × 105 cells/well (2 mL per well). After the
cells were allowed to resume exponential growth for 24 h, they were exposed to 1 and 2 at various
concentrations for 24 h at 37 ◦C. The cells were washed twice with 1 mL of PBS and lysed with 100 µL of
RIPA lysis buffer (ultrapure water, 5 M NaCl, 1 M Tris-HCl pH 8.0, 2% sodium deoxycholate, 10% SDS,
IGEPAL, protease and phosphatase inhibitor) for 5–10 min at 4 ◦C. The cell lysates were scraped
from the wells and transferred to separate 1.5 mL microtubes. The supernatant was then collected
after centrifugation (13,000 rpm, 4 ◦C for 15 min) and the total protein content of each sample was
quantified via a Bradford’s assay. Cell lysates were transferred to 2 mL glass vials and then digested
with ultrapure 60% HNO3 (50 µL) at 110 ◦C for 96 h. The resulting solution was diluted to 1 mL (2–4%
(v/v) HNO3) with ultrapure Milli-Q water, sonicated for 45 min and filtered through 0.45 µm filters.
Cu content of each sample was quantified by ICP-MS and expressed as per mg of protein. Re was used
as an internal standard. Cu and Re were measured at m/z 64 and m/z 186, respectively. Metal standards
for calibration curve (0, 1, 2, 5, 10, 20, 40 ppb) were prepared. All readings were performed in six
replicates in He mode.
2.8. Spectrophotometric and pH-Potentiometric Measurements
Agilent Carry 8454 diode array spectrophotometer was used to record the UV–Vis spectra in the
interval 200–800 nm. The path length was 1 or 2 cm. Solution stability of ligands HL1 and HL2 and their
copper(II) complexes was monitored at various pH values by UV–Vis spectroscopy. The conditional
stability constants (K’) of 1 and 2 were attempted to be calculated at pH 5.90 based on the spectral
changes via the displacement reaction with ethylenediaminetetraacetic acid (EDTA) in the presence
50 mM 2-(N-morpholino)ethanesulfonic acid (MES) and 0.1 M KCl. In this competition experiment,
the samples contained 50 µM complex and the concentration of EDTA was varied in the range from 0
to 422 µM. The reaction of 1 and 2 with glutathione (GSH) was studied at 25.0 ± 0.1 ◦C on Hewlett
Packard 8452A diode array spectrophotometer using a special, tightly closed tandem cuvette (Hellma
Tandem Cell, 238-QS, Altmann Analytik GmbH & Co. KG, Munich, Germany). The reactants were
held separate until the reaction was triggered. Both isolated pockets of the cuvette were completely
deoxygenated by bubbling a stream of argon for 10 min before mixing the reactants. Spectra were
recorded before and then immediately after the mixing, and changes were followed until no further
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absorbance change was observed. One of the isolated pockets contained the reducing agent (12 mM
GSH), and the other contained the studied compound (100 µM). The pH of all the solutions was
adjusted to 7.40 by 50 mM (0.1 M KCl) HEPES buffer. The pH-potentiometric titrations were performed
on samples containing HL2 at 3 mM concentration with a KOH solution in the presence of 0.1 M KCl at
25.0 ± 0.1 ◦C. An Orion 710A pH-meter equipped with a Metrohm combined electrode (type 6.0234.100,
Metrohm Inula GmbH, Vienna, Austria) and a Metrohm 665 Dosimat burette (Metrohm Inula GmbH,
Vienna, Austria) were used for the pH-metric titrations. The electrode system was calibrated to
the pH = −log[H+] scale using titrations of HCl with KOH according to the method suggested by
Irving et al. [41]. The average water ionisation constant (pKw) is 13.76 ± 0.05 in water. Argon was also
passed over the solutions during the titrations. UV–Vis titration was performed for HL1, which is less
water-soluble compared to HL2, and the data were evaluated up to pH 6. Calculation of the pKa values
was performed with the computer programs PSEQUAD (HL1) and HYPERQUAD (HL2) [42].
2.9. Tyrosyl Radical Reduction in Human R2 RNR Protein
The time-dependent kinetics of tyrosyl radical destruction in human R2 ribonucleotide reductase
protein (hR2) by 3-AP and HL2 were measured by EPR spectroscopy at 30 K, on a Bruker Elexsys II
E540 EPR spectrometer with an Oxford Instruments ER 4112HV helium cryostat. The experimental
conditions were: microwave power 3.2 mW, modulation amplitude 5 G, modulation frequency 100 kHz,
and conversion time 0.0293 s. Spectra were recorded and analysed using the Bruker Xepr software.
The concentration of the tyrosyl radical was determined by double integration of EPR spectra recorded
at non-saturating microwave power levels and compared with the copper standard [43]. Purified,
recombinant, iron-reconstituted hR2 [44] was obtained from the Department of Biochemistry and
Biophysics, Stockholm University, Sweden. The samples containing 20 µM hR2 in 50 mM Hepes
buffer, pH 7.60/100 mM KCl/5% glycerol, and 20 µM 3-AP or HL2 in 1% (v/v) DMSO/H2O, and 2 mM
dithiothreiotol were incubated for indicated times and quickly frozen in cold isopentane. The same
sample was used for repeated incubations at room temperature. The experiments were performed
in duplicates.
2.10. EPR Spin Trapping Experiments
The generation of paramagnetic intermediates was monitored by cw-EPR spectroscopy using
the EMX spectrometer (Bruker). The EPR spectra were measured with following experimental
parameters: X-band, room temperature, microwave frequency, 9.431 GHz; modulation frequency,
100 kHz; field modulation amplitude, 2 G; time constant, 10 ms; scan time, 41s (5 scans). Distilled
and deionised water was used for the preparation of DMSO/water solutions. The spin trapping agent
5,5-dimethyl-1-pyrroline N-oxide (DMPO; Sigma-Aldrich, Schnelldorf, Germany) was distilled prior
to the application.
2.11. Western Blotting Experiments
The experiments were performed, as described previously [21].
3. Results and Discussion
3.1. Synthesis and Characterisation of the HL1, HL2, Cu(II) Complexes 1 and 2 and Fe(III) Complex 3
HL1 was obtained by the condensation reaction of 3-N-(tert-butyloxycarbonyl)amino-pyridine-
2-carboxaldehyde with 2-pyridinamidrazone in the presence of 12 M HCl in 1:1:1 molar ratio in ethanol
followed by Boc-deprotection in 4 M HCl/ethyl acetate (EtOAc) (1:6) at 45 ◦C in 74% yield (Scheme S1).
The reaction was monitored by positive ion ESI mass spectrometry. First, the formation of Boc-HL1
was confirmed by the presence of the peak at m/z 341.16 attributed to [Boc-HL1+H]+, and then the
Boc-deprotection by the presence of the peak at m/z 241.23 assigned to [HL1+H]+. It was noticed
that Boc-deprotection performed under more severe conditions by prolonged boiling the Boc-HL1
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in the presence of excess 12 M HCl (1:5) in ethanol/water (3/1) afforded another product (HL1a) with
the same molecular mass as HL1 as confirmed by ESI mass spectrum (see Supporting Information
(SI) for the synthesis of HL1a and Scheme S1 for its line drawing). The formation of two different
products HL1 (crystallisation in ethyl acetate/hexane) and HL1a (crystallisation from mother liquor
as [H3L1a]Cl2·2H2O) was confirmed by single crystal X-ray diffraction analyses (see Figure 1 and
Figure S4 in SI) and multinuclear NMR spectroscopy.
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It was envisioned that HL1 may exist in two tautomeric forms AHL1 and BHL1 (Scheme S2 in
SI). However, the 1H NMR spectrum of HL1 in DMSO-d6 showed only one set of signals, which was
attributed to the tautomeric form AHL1. The presence of two amine groups was evidenced by two
proton singlets at 6.85 (H16′) and 7.10 (H7′) ppm in the 1H NMR spectrum, as well as by the N-H
resonances at 71.27 (N16′ ) and 76.02 (N7′ ) ppm in the 1H15N HSQC spectrum (for atom numbering see
Scheme S3 in SI).
The reaction of HL1 with CuCl2·2H2O in methanol in 1:1 molar ratio under reflux afforded a
brown solid that was purified by preparative HPLC to give 1·H2O (Figure S1). The positive ion ESI
mass spectrum showed peaks at m/z 338.14 and 303.17 which could be assigned to [CuII(HL1)Cl]+ and
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[CuI(HL1)]+, respectively (Figure S2). The X-ray diffraction quality single crystals of 1 were grown in
methanol. Several attempts to prepare the Fe(III) complex with HL1 in a similar manner failed.
HL2 was synthesised by the reaction of 3-N-(tert-butyloxycarbonyl)amino-2-pyridinecarboxaldehyde
with S-methylisothiosemicarbazidium chloride in the presence of excess hydrochloric acid followed by
neutralisation of the reaction mixture with NaHCO3 in water in 67% yield. The positive ion ESI mass
spectrum showed a peak at m/z 210.06 attributed to [HL2+H]+. Single crystals of HL2 were obtained
from ethanol/water (3/1) mixture. The 2D NMR spectra of HL2 (in DMSO-d6) contain two sets of signals
in 1.6:1 intensity ratio, which were attributed to thioamide (form AHL2) E/Z-isomers (Schemes S2 and
S4 in SI). The E-isomer is stabilised by the intramolecular N–H···N hydrogen bond (Scheme S4 in
SI). In accord with this, the proton resonance of H7 is down-field shifted to 6.87 ppm (dominant set,
E-isomer); H7 in the minor isomer is seen at 6.67 ppm (Z-isomer). As for HL1, the presence of two
amine groups was confirmed by two proton singlets displayed by E-isomer at 6.87 (H7) and 6.82 (H13)
and Z-isomer at 6.90 (H13) and 6.67 (H7) ppm, as well as by the N-H resonances for E-isomer at 66.7
(N7) and 80.5 (N13) or for Z-isomer at 70.9 (N7) and 83.7 (N13) ppm in the 1H15N HSQC spectra.
The reaction of HL2 with CuCl2·2H2O in methanol in a 1:1 molar ratio afforded dark-green crystals
of 2 of X-ray diffraction quality. The positive ion ESI mass spectrum showed peaks at m/z 271.15 and
307.13 which could be assigned to [CuII(L2)]+ and [CuII(HL2)Cl]+, respectively. Black microcrystalline
product 3·0.75H2O was prepared from HL2, Fe(NO3)3·9H2O and triethylamine in 2:1:2 molar ratio in
methanol. The positive ion ESI mass spectrum showed a peak at m/z 472.20, which could be assigned
to [Fe(L2)2]+ (Figure S3).
3.2. X-ray Crystallography
The results of X-ray diffraction studies of HL1, [H3L1a]Cl2·2H2O, HL2, [Cu(HL1)Cl2] (1) and
[Cu(HL2)Cl2] (2) are shown in Figure 1 and Figure S4. The free ligand HL1 crystallised in the
orthorhombic space group Pna21, HL2 and 1 in the monoclinic space group P21/c, while 2 in the triclinic
centrosymmetric space group P1.
Both, HL1 and HL2 in 1 and 2 act as neutral tridentate ligands. HL1 forms one six-membered
and one five-membered chelate rings upon coordination to Cu(II), while HL2 forms two
five-membered chelate rings. The coordination polyhedron around Cu(II) in 1 is intermediate between
trigonal-bipyramidal and square-pyramidal (τ5 = 0.58). The same distorted coordination geometry
was reported previously for a closely related complex [Cu(appc)Cl2] (appc = 2-acetylpyridine-
pyridine-2-carboxamidrazone) (τ5 = 0.58) [45]. The coordination geometry of copper(II) in 2 in
contrast is very close to square-pyramidal (τ5 = 0.11) [46]. The tridentate ligand HL2 is bound to
Cu(II) via nitrogen atoms N1, N3 and N5. The coordination polyhedron is further completed by two
chlorido co-ligands Cl1 and Cl2. The configuration adopted by the ligand in 2 differs considerably
from that adopted by HL2 in the solid-state. A two-fold rotation of the pyridine ring around
C5–C6 bond and of the isothioamide unit around N4–C7 bond in HL2 are required to achieve the
configuration of the isothiosemicarbazone ligand in 2. As in other Cu(II) complexes with tridentate
isothiosemicarbazones [34], the thiomethyl group is not involved in coordination to the 3d transition
metal atom.
3.3. Solution Chemistry of HL1, HL2 and Their Cu(II) Complexes (1 and 2)
The solution behaviour of Cu(II) complexes with triapine and other pyridine-2 carboxaldehyde
thiosemicarbazones has been reported in our recent works [19,21,47,48], revealing the predominant
formation of [CuL]+ complexes in a wide pH range, including the physiological pH, where L is the
deprotonated monoanionic ligand. The stability of this type of complex with the (Npyridine,N,S−)
donor set is so high that its decomposition is negligible even at low micromolar concentrations.
However, the solution stability data was never reported for the carboxamidrazone and the
pyridine-2-carboxaldehyde S-methylisothiosemicarbazone free ligands and their Cu(II) complexes.
HL2 and 2 were selected for a more detailed solution study, since the aim was to reveal the solution
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stability differences between Cu(II) complexes of the isothiosemicarbazone “S-methyltriapine” HL2
with (N,N,N) donor set and the thiosemicarbazone (triapine) with (N,N,S) donor atoms. In addition,
the solution chemical properties of HL1 and 1 were also monitored by UV–Vis spectrophotometry.
Firstly, proton dissociation processes of HL2 were followed by pH-potentiometry in water (Figure S5).
Notably, HL1 could not be studied by this technique, due to its limited water-solubility. Based on
the recorded titration curves of HL2, pKa = 4.96 ± 0.05 was determined, which can be attributed to
the deprotonation of the pyridinium nitrogen. This value is higher than that for triapine (4.25) [48].
The hydrolytic stability of this free ligand was checked by a second titration with KOH following
back-acidification of the initially titrated sample, and a similar pKa (5.05 ± 0.08) was obtained.
pKa values (pK1 ~ 2.4 and pK2 ~ 3.5) for HL1 could be only estimated via spectrophotometric titrations
(Figure S6), since the spectra revealed time-dependence. To further investigate the solution stability
of both ligands, UV–Vis spectra were recorded under argon at physiological pH using HEPES buffer
(Figure 2) and demonstrated significant changes with time indicating the possible decomposition of the
compounds. In case of HL2 most likely the elimination of CH3SH takes place in agreement with the
appearance of the characteristic mercaptan odour of the samples and it seems that this transformation
has no marked effect on the pKa of the pyridinium nitrogen. The time dependence of the absorbance
spectra was also followed at pH 2.2 (HCl) and 9.8 (NaOH), showing similar spectral changes. However,
the process becomes faster with increasing pH (Figure S7c), while it was significantly slower in pure
water at pH 6.3 (without electrolyte and buffer components). The spectral changes of HL1 (Figure S8)
were reminiscent of those of HL2, although the rate of the reaction was the slowest at pH 7.4. In this
case, the significant decrease of the absorbance band at 374–400 nm is most likely the consequence of
the less extended conjugation system in the molecule, due to the cleavage of one of the C=N Schiff base
bonds. This type of hydrolysis is typically catalysed by acid or base. Additionally, the Cu(II) binding
ability of both ligands was considerably diminished confirming their partial decomposition as a large
difference in the spectra of samples containing free ligands kept at acidic pH (for 0 and 24 h) prior to
the addition of Cu(II) ions and adjusting the pH to 7.4 (Figure S9). Although the spectral changes are
relatively slow in all cases based on these findings, the complete wide pH range solution equilibrium
studies could not be performed.
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The solution stability of 1 and 2 was also investigated, and time-dependent UV–Vis spectra
recorded at pH 2, 7.4 and 10 (Figure S10) demonstrated only minor spectral changes, indicating that
the complexes are more robust at physiological pH than their respective ligands.
Next, the thermodynamic stability of complexes 1 and 2 was investigated by competition reactions
with EDTA at pH 5.9 (Figure 3 for 2). This pH was chosen as comparable conditional stability constants
are available for analogous complexes. Representative UV–Vis spectra are shown in the wavelength
range where only 2 and the free ligand absorb light. High excess of EDTA was needed to achieve
measurable ligand replacement, and logK’5.9 = 7.38 ± 0.02 as conditional stability constant for 2 was
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obtained, and in case of 1 log K’5.9 = 8.20 ± 0.02 was determined. These constants are lower than that
of triapine (12.88), ref. [48] implying the weaker Cu(II) binding ability of both HL1 and HL2 compared
to the pyridine-2-carboxaldehyde thiosemicarbazones.Biomolecules 2020, 10, x FOR PEER REVIEW 12 of 22 
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3.4. Cytotoxicity
Complexes 1–3 were tested for antiproliferative acti inst two cancer cell lines—ovarian
carcinoma A2780 and its cisplatin-resistant analogue 2780cis, as well as noncancerous human
embryonic kidney cell line HEK293. Their cytotoxicity, reflected by 50% inhibitory concentration (IC50)
values, was compared to that of triapine, cisplatin and respective free ligands (Table 2 and Figure
S11). The differences in the cytotoxicity between cisplatin-sensitive and cisplatin-resistant cell lines are
represented by resistance factors (RF). The selectivity to cancer cells over healthy noncancerous cells is
represented by the selectivity factor (SF).
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Fr Table 2, it is seen that the free ligands HL1 and HL2 were only marginally cytotoxic, and that
their coordination to Cu(II) or Fe(III) resulted in a significant improvement of cytotoxicity, 14- and
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144-fold change for Cu(II) complexes 1 and 2, respectively, and nearly 5-fold increase for Fe(III)
complex 3. Complex 2 was more active than triapine and cisplatin in cisplatin-resistant A2780cis cell
line. In general, all compounds were similarly cytotoxic in both A2780 and A2780cis cells, which is
reflected by their low RFs. Unfortunately, these compounds also demonstrated comparable toxicity in
noncancerous HEK293 cells, similar to triapine and other previously reported thiosemicarbazones [21].
4. Investigation of Mechanism of Action
4.1. Intracellular Accumulation
It is known that CuCl2 salt displays anticancer activity in a range of cancer cells lines, which may
be attributed to intracellular Cu overload which leads to ROS production, and altered cancer cell
signalling [49,50]. However, despite the disruption of the natural homeostasis of this endogenous metal
ion, the cytotoxicity of CuCl2 is very limited and manifested only at high micromolar concentrations.
This is related to the hydrophilic nature of the inorganic salt, which prevents its efficient uptake by the
cells. Since both HL1 and HL2 did not show any reasonable anticancer activity, it was anticipated that
the improved cytotoxicity of the metal complexes was directly dependent on the metal centre. In order
to compare the intracellular Cu accumulation between 1, 2 and CuCl2, Cu content in A2780 cells treated
with these compounds (using 0.3 × IC50 concentration) was measured by ICP-MS (Table 2 and Figure 4).
Cellular accumulation of the drugs depends on the cell membrane permeability and is known to
increase when cellular membranes are compromised. Therefore, cells were treated with the non-toxic
equipotent concentrations of the drugs with respect to their killing potential. In agreement with the
initial hypothesis, both complexes demonstrated similar Cu accumulation as CuCl2 (0.64–0.76 nmol
Cu/mg protein). Similarly, for IC50 concentrations, complexes 1 and 2 also demonstrated non-significant
differences in Cu accumulation (1.1 ± 0.3 and 0.76 ± 0.17 nmol Cu/mg protein for 1 and 2, respectively).
This result indicates that despite significant differences in the cytotoxicity of complexes 1, 2 and CuCl2,
the active Cu concentration in drug-treated cancer cells is similar for all three compounds, suggesting
that cytotoxicity may be determined by the efficacy of intracellular delivery of Cu ions. However,
it should be emphasised that almost identical Cu concentration was achieved when the concentration
of 2 was ca. 12, and 60 times lower than the concentrations of 1, and CuCl2, respectively. The improved
cytotoxicity of 2 may be related to a more efficient intracellular delivery or a less efficient cellular efflux.
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Statistical analysis was performed by two-t il -test using GraphPad Prism software (Gr phPad
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4.2. Electro hemistry
Both, Cu and Fe are redox-active metals, hich are essential for the normal cellular function,
and their overload triggers the integrative cellular response, including oxidative and proteostatic
stress. Since the role of the metal ion in the anticancer activity of complexes 1 and 2 was evident
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(see Table 2), complexes 1–3 were investigated for their ability to release metal ions within the biologically
accessible window, which may further lead to the induction of cellular stress. To investigate the redox
properties of 1–3, a detailed electrochemical study was performed by cyclic voltammetry, as well
as UV–Vis–spectroelectrochemistry.
The cyclic voltammogram of 1 in DMSO/n-Bu4NPF6 at Pt working electrode showed one
irreversible reduction peak with cathodic peak potential Epc = −0.76 V vs Fc+/Fc0 (Figure 5a). The first
irreversible reduction step can be attributed to the Cu(II) → Cu(I) process, followed by ligand
release from the unstable Cu(I)L complex. Similar to 1, complex 2 decomposed upon reduction;
however, even more intricate redox behaviour was observed with two irreversible cathodic waves at
Epc1 = −0.67 V and Epc2 = −1.05 V vs Fc+/Fc0 (Figure 5b). To further explore the chemical processes
occurring at the first reduction step of 2, the in situ spectroelectrochemical UV–Vis and cyclic
voltammetric experiments were carried out under an argon atmosphere in a special thin layer
spectroelectrochemical cell with a microstructured honeycomb working electrode. The UV–Vis spectra
measured upon cathodic reduction of 2 revealed a new optical band at 373 nm in the region of the first
reduction peak, as well as a decrease of the intensity of the two bands at 284 and 448 nm (Figure 6a).
Upon scan reversal, the product that was formed upon reduction of Cu(II) to Cu(I) was not reoxidised
back to the initial state (Figure 6b). This unambiguously indicates that Cu(I) species were not stable
and irreversibly decomposed with the full or partial ligand release. On the contrary, ferric complex 3
exhibited different redox behaviour with almost reversible electrochemical reduction with the first
reduction event at E1/2 = –0.81 V vs Fc+/Fc (Figure 5c).
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complexes, there were no significant spectral changes observed, and the initial spectra could not be 
recovered. 
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Figure 6. In situ UV–Vis spectroelectrochemistry for 2 in DMSO/n-Bu4NPF6 (scan rate of 10 mV s−1,
Pt-microstructured honeycomb working electrode): (a) Evolution of UV−Vis spectra in 2D projection
in the forward scan; (b) UV–Vis spectra detected simultaneously upon the cyclic voltammetric scan
(Inset—respective cyclic voltammogram).
4.3. Intracellular Release of Metal Ions
Cancer cells are characterised by the high levels of GSH, the low molecular mass antioxidant
tripeptide, and a reducing intracellular environment. Following the observations from the cyclic
voltammetry experiments, it was investigated whether complexes 1 and 2 could release Cu ions in
the presence of GSH. The reduction of 1 and 2 by GSH was followed by UV–Vis spectrophotometry
under the anaerobic condition at pH 7.4. A tightly closed tandem cuvette was used, containing Cu
complexes in one of the pockets, and 120 equiv. GSH in the other one. After triggering the reaction,
the first recorded spectrum (10 s) revealed significant spectral changes, due to the fairly fast reduction
of the complexes (Figure S12), similar to the spectroelectrochemical UV–Vis behaviour summarised in
Figure 6a. The reaction was found to be extremely fast for 1 and the final spectrum corresponded to
that of the free ligand HL1. However, the generated final spectrum in case of 2 does not correspond to
the ligand HL2, the λmax (388 nm) is somewhat shifted to the higher wavelengths (Figure S8a, λmax of
HL2: 362 nm under the same condition). When passing oxygen through the solutions of the reduced
complexes, there were no significant spectral changes observed, and the initial spectra could not
be recovered.
Upon cathodic reduction of 3 in DMSO/n-Bu4NPF6 at the first electron transfer new absorption
bands at 649, 395 and 289 nm arise with a simultaneous decrease of the initial optical band at 500 nm
via isosbestic points at 550, 444, 274 and 300 nm (Figure 7a). Additionally, upon voltammetric reverse
scan nearly full recovery of the initial optical bands was observed, attesting the chemical reversibility
Biomolecules 2020, 10, 1336 16 of 22
of the cathodic reduction even at low scan rates (Figure 7b). These results are comparable with those
reported for other Fe(III)–TSC complexes [27,51].
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Figure 7. Spectroelectrochemistry of 3 in n-Bu4NPF6/DMSO in the region of the first cathodic
peak. (a) UV–Vis spectra detected simultaneously during the in situ reduction (Pt-microstructured
honeycomb working electrode, scan rate v = 10 mV s−1); (b) potential dependence of UV−Vis spectra
(Inset—respective cyclic voltammogram with the colour-highlighted potential region, where spectra
were recorded).
Based on the results of the spectroelectrochemical experiments, it was concluded that complexes
1–3 can release metal ions in the reducing cellular environment. However, even minor changes in
the structure of the complexes significantly affected chemical transformations accompanying their
reduction. The reduction of complex 1 resulted in the irreversible release of inactive ligand HL1 and Cu
ions; therefore, its anticancer activity may be fully attributable to the Cu centre. Similarly, the reduction
of complex 2 also resulted in an irreversible release of Cu ions; however, it was accompanied by the
formation of a new organic species, different from HL2, which has not been identified. On the contrary,
Fe co plex 3 demonstrated reversible redox cycling, which commonly leads to sustainable cellular
ROS production.
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Ex vivo ROS detection. To further investigate the redox processes occurring upon reversible
reduction of complex 3, we performed EPR spin trapping experiments with [FeII(L2)2], in comparison
with the FeII-triapine complex, FeII(3-APH−1)2, ref. [10] using DMPO as the spin trapping agent
(Figures S13 and S14). The reaction mixture contained 0.45 mM free ligand in 1% (v/v) DMSO/H2O,
0.04 M DMPO, freshly prepared aqueous solution of FeSO4 (0.22 mM) to form bis-ligand complexes,
and 0.1 M H2O2, and the EPR spectra were recorded immediately. As shown in Figure S13, for both,
[FeII(3-APH−1)2] and [FeII(L2)2] the rapid formation of the DMPO-OH• spin-adducts with similar
yields was confirmed in both cases. No production of ROS was observed for free ligands (3-AP and
HL2), confirming the crucial role of Fe for ROS generation. More stable adducts were observed
in 5% (v/v) DMSO/H2O system where the carbon centred spin-adducts dominated, as previously
reported for dithiothreitol-reduced [FeII(3-APH−1)2] in the presence of DMPO [11]. In this case, DMSO
acted as a HO• scavenger generating methyl radicals which are trapped by DMPO. The EPR spin
trapping experiments suggest that reversible reduction of complex 3 led to the production of the
Fenton-generated OH• radicals, similar to the FeII-triapine complex, which may be responsible for
cancer cell death.
4.4. hR2 RNR Inhibition by HL2
The results presented thus far, regarding the lead compound, complex 2, showed that HL2
coordination to Cu(II) resulted in a significant improvement of its cytotoxicity, which is most likely
determined by its efficient intracellular delivery of copper ions. To further confirm that the cytotoxicity
of 2 is determined by the ligand’s ability to serve as a copper delivery vehicle, further experiments
with the ligand, HL2, were performed. Namely, since HL2 is structurally related to 3-AP, which has
been shown to be a potent hR2 RNR inhibitor, tyrosyl radical destruction in hR2 by HL2 was measured
by EPR spectroscopy at 30 K and compared to that by 3-AP. 3-AP efficiently inhibits mammalian R2
RNR in the presence of an external reductant (GSH or DTT), and as reported recently [21], several
studies have shown that it is the formed [FeII(3-APH–1)2] species that is responsible for the R2-specific
RNR inhibitory effect of 3-AP [9–11,52,53].
When equimolar amounts of protein and ligand were incubated in the presence of DTT, 50% tyrosyl
radical reduction was observed after 45 s with 3-AP, and 5 min with HL2 (Figure 8). Furthermore,
3-AP reduced 100% radical after approximately 3 min, which is in agreement with previously published
results for mouse R2 RNR [10]. However, in the same experimental conditions, HL2 was not able to
reduce 100% radical in hR2 even after 10 min. These results indicate that HL2 is not as efficient hR2
inhibitor as 3-AP, in agreement with its marginal cytotoxicity, and provides further evidence about its
role as an intracellular copper delivery vehicle, contributing to the cytotoxic activity of complex 2.
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Figure 8. Tyrosyl radical reduction in human R2 RNR protein by 3-AP and HL2 in the presence of an
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glycerol, and 20 µM 3-AP or HL2 in 1% (v/v) DMSO/H2O, and 2 mM dithiothreiotol (DTT). Error bars
are the standard deviation from two independent experiments.
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4.5. The Effects of Cu Overload on Cancer Cell Signalling
While ROS-inducing properties of Cu ions, as well as Cu complexes, have been exhaustively
studied, their effects on cancer signalling cascades have been largely overlooked [54]. Recently,
the microarray analysis of Cu-overloaded colon cancer cells revealed the disruption of genes involved
in unfolded protein response (UPR), proteasomal degradation and autophagy—the major pro-survival
cellular responses [49]. However, prolonged Cu treatment led to the activation of caspase-dependent
and -independent modes of cell death [49]. Several Cu-thiosemicarbazone complexes were also
shown to induce UPR, autophagy and antioxidant defence [21,55,56]. Therefore, the effects of the
most active complex 2 on the expression of pro-apoptotic UPR marker CHOP were determined,
as well as the antioxidant defence marker Nrf2 (Figure 9). When A2780 cells were treated with
increasing concentrations of 2 for 24 h, the increase of both, Nrf2 and CHOP was observed even at low
concentrations (1 µM). In addition, the drug treatment interference with cell cycle was investigated by
monitoring the markers playing an important role in the cell cycle progression through gap phases,
namely, cyclin D1 (G1/S) and cyclin B1 (G2/M). While no changes in cyclin D1 expression were observed,
the decrease in cyclin B1 expression indicated the cell halt at G2/M phase and delayed progression
to mitosis. This observation was in stark contrast with other Cu-TSC complexes which caused cell
cycle arrest at G1/S characterised by the decreased expression of cyclin D1 [21]. Finally, the effects of
complex 2 on the PARP cleavage were investigated, which is a key event occurring during apoptosis.
As expected, the expression of total PARP decreased, while the expression of cleaved PARP increased
in a dose-dependent manner, indicating that complex 2 induced apoptotic cell death in A2780 cells,
apoptotic cell death in A2780 cells.
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5. Conclusions
While the entrance of triapine as an anticancer agent into clinical trials has revealed its
limitations, due to side effects and ineffectiveness against solid tumours, the class of α-N-heterocyclic
thiosemicarbazones, and their metal complexes, have shown promising potential for further
development as anticancer drugs. Herein, two triapine derivatives HL1 and HL2 were prepared,
which act as neutral N,N,N-tridentate ligands in their Cu(II) complexes, in contrast to triapine,
which coordinates first-row transition metals through N,N,S donor atoms. The spectroelectrochemical
experiments indicated that Cu complexes 1 and 2 underwent irreversible reduction of Cu(II) centres
accompanied by the release of the free ligands and Cu(I) ions. On the other hand, Fe(III) complex 3,
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where HL2 acts as monoanionic ligand, was shown to reversibly redox cycle leading to the production of
the hydroxyl radical. The lead complex 2 demonstrated comparable cytotoxicity to triapine, but was less
toxic to healthy cells. Based on the mechanistic investigations in ovarian cancer cells, it is likely that the
non-cytotoxic HL1 and HL2 play an important role in the delivery of Cu, resulting in the disruption of
the tightly regulated intracellular balance of this essential metal ion. Thus, HL1 and HL2 act as effective
vehicles for intracellular Cu delivery and may be of interest for future therapeutic development.
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